{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:10:31Z","timestamp":1776273031526,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00384-019-03271-9","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T08:03:37Z","timestamp":1554710617000},"page":"1053-1059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system"],"prefix":"10.1007","volume":"34","author":[{"given":"M. P.","family":"Ballester","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Marti-Aguado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fullana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"Bosca-Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tosca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Navarro-Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Anton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Minguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"3271_CR1","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","volume":"11","author":"M Hardbord","year":"2017","unstructured":"Hardbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Moln\u00e1r T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F, European Crohn\u2019s and Colitis Organisation (ECCO) (2017) Third European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohn Colitis 11:769\u2013784. \n                    https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx009","journal-title":"J Crohn Colitis"},{"key":"3271_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1365-2036.2011.04701.x","volume":"34","author":"SP Travis","year":"2011","unstructured":"Travis SP, Higgins PD, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, O\u2019Morain C, Pan\u00e9s J, Sturm A, Reinisch W, Kamm MA, D\u2019Haens G (2011) Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 34:113\u2013124. \n                    https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04701.x","journal-title":"Aliment Pharmacol Ther"},{"key":"3271_CR3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/ajg.2011.67","volume":"106","author":"AC Ford","year":"2011","unstructured":"Ford AC, Achkar JP, Khan KJ, Kane SV, Talley NJ, Marshall JK, Moayyedi P (2011) Efficacy of 5-ASA in UC: a meta-analysis. Am J Gastroenterol 106:601\u2013616. \n                    https:\/\/doi.org\/10.1038\/ajg.2011.67.","journal-title":"Am J Gastroenterol"},{"key":"3271_CR4","doi-asserted-by":"publisher","first-page":"CD000543","DOI":"10.1002\/14651858.CD000544.pub4.","volume":"4","author":"Y Wang","year":"2016","unstructured":"Wang Y, Parker CE, Feagan BG, MacDonald JK (2016) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 4:CD000543. \n                    https:\/\/doi.org\/10.1002\/14651858.CD000544.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"3271_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/j.1572-0241.2005.41442.x","volume":"100","author":"FS Velayos","year":"2005","unstructured":"Velayos FS, Terdiman JP, Walsh JM (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100:1345\u20131353","journal-title":"Am J Gastroenterol"},{"key":"3271_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487\u2013497. \n                    https:\/\/doi.org\/10.1056\/NEJMra050100","journal-title":"N Engl J Med"},{"key":"3271_CR7","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/ibd.20189","volume":"13","author":"P Cerveny","year":"2007","unstructured":"Cerveny P, Bortlik M, Vlcek J, Kubena A, Luk\u00e1s M (2007) Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 13:1244\u20131249. \n                    https:\/\/doi.org\/10.1016\/j.crohns.2007.08.002.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"3271_CR8","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1080\/00365521.2016.1195870","volume":"51","author":"P Bager","year":"2016","unstructured":"Bager P, Julsgaard M, Vesteergard T, Christensen LA, Dahlerup JF (2016) Adherence and quality of care in IBD. Scand J Gastroenterol 51(11):1326\u20131331. \n                    https:\/\/doi.org\/10.1080\/00365521.2016.1195870","journal-title":"Scand J Gastroenterol"},{"key":"3271_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","volume":"114","author":"S Kane","year":"2003","unstructured":"Kane S, Huo D, Aikens J, Hanauer S (2003) Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114:39\u201343","journal-title":"Am J Med"},{"key":"3271_CR10","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s00535-012-0721-x","volume":"48","author":"A Kawakami","year":"2013","unstructured":"Kawakami A, Tanaka M, Nishigaki M, Naganuma M, Iwao Y, Hibi T, Sanada H, Yamamoto-Mitani N, Kazuma K (2013) Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol 48:1006\u20131015. \n                    https:\/\/doi.org\/10.1007\/s00535-012-0721-x","journal-title":"J Gastroenterol"},{"key":"3271_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2036.2008.03865.x","volume":"29","author":"P Higgins","year":"2008","unstructured":"Higgins P, Rubin DT, Kaulback K, Schoendfield PS, Kane SV (2008) Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and costs of ulcerative colitis flares. Aliment Pharmacol Ther 29:247\u2013257. \n                    https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03865.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"3271_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/apt.12013","volume":"36","author":"N Khan","year":"2012","unstructured":"Khan N, Abbas AM, Bazzano LA, Koleva YN, Krousel-Wood M (2012) Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-years retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther 36:755\u2013764. \n                    https:\/\/doi.org\/10.1111\/apt.12013","journal-title":"Aliment Pharmacol Ther"},{"key":"3271_CR13","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1136\/gut.2005.070896","volume":"54","author":"TP Staa Van","year":"2005","unstructured":"Van Staa TP, Card T, Logan RF, Leufkens HG (2005) 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54:1573\u20131578","journal-title":"Gut"},{"key":"3271_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1471-230X-12-132","volume":"12","author":"D Mitra","year":"2012","unstructured":"Mitra D, Hodgkins P, Yen L, Davis KL, Cohen RD (2012) Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol 12:132. \n                    https:\/\/doi.org\/10.1186\/1471-230X-12-132","journal-title":"BMC Gastroenterol"},{"key":"3271_CR15","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1007\/s10620-007-9968-0","volume":"53","author":"S Kane","year":"2008","unstructured":"Kane S, Shaya F (2008) Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 53:1020\u20132024","journal-title":"Dig Dis Sci"},{"issue":"6","key":"3271_CR16","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1097\/MIB.0b013e318280b1b8","volume":"19","author":"N Khan","year":"2013","unstructured":"Khan N, Abbas AM, Koleva YN, Bazzano LA (2013) Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose. Inflamm Bowel Dis 19(6):1123\u20131129. \n                    https:\/\/doi.org\/10.1097\/MIB.0b013e318280b1b8","journal-title":"Inflamm Bowel Dis"},{"key":"3271_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.crohns.2010.01.005","volume":"4","author":"F Bermejo","year":"2010","unstructured":"Bermejo F, L\u00f3pez-San Rom\u00e1n A, Algaba A, Guerra I, Valer P, Garc\u00eda-Garz\u00f3n S, Piqueras B, Villa C, Bermejo A, Rodr\u00edguez-Agull\u00f3 JL (2010) Factors that modify therapy adherence in patients with inflammatory bowel disease. J Crohn Colitis 4:422\u2013426. \n                    https:\/\/doi.org\/10.1016\/j.crohns.2010.01.005","journal-title":"J Crohn Colitis"},{"issue":"2","key":"3271_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.17235\/reed.2016.4620\/2016.","volume":"109","author":"A Algaba","year":"2017","unstructured":"Algaba A, Guerra I, Garcia Garcia de Pareces A, Hern\u00e1ndez Tejero M, Ferre C, Bonillo D, Aguilera L, L\u00f3pez-Sanrom\u00e1n A, Bermejo F (2017) What is the real life manteinance mesalazine dose in ulcerative colitis? Rev Esp Enferm Dig 109(2):114\u2013121. \n                    https:\/\/doi.org\/10.17235\/reed.2016.4620\/2016.","journal-title":"Rev Esp Enferm Dig"},{"issue":"7","key":"3271_CR19","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/j.1572-0241.2007.01212.x","volume":"102","author":"JP Ediger","year":"2007","unstructured":"Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, McPhail C, Deering K, Bernstein CN (2007) Predictor of medication adherence in inflammatory bowel disease. Am J Gastroenterol 102(7):1417\u20131426","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"3271_CR20","doi-asserted-by":"publisher","first-page":"0214","DOI":"10.1111\/codi.13393","volume":"18","author":"W Li","year":"2016","unstructured":"Li W, Zhang ZM, Jiang XL (2016) Once daily versus multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis. Color Dis 18(7):0214\u20130223. \n                    https:\/\/doi.org\/10.1111\/codi.13393","journal-title":"Color Dis"},{"issue":"Suppl","key":"3271_CR21","doi-asserted-by":"publisher","first-page":"5A","DOI":"10.1155\/2005\/269076","volume":"19","author":"MS Silverberg","year":"2005","unstructured":"Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Pe\u00f1a AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl):5A\u201336A","journal-title":"Can J Gastroenterol"},{"key":"3271_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gastrohep.2012.11.001","volume":"36","author":"F Gomoll\u00f3n","year":"2013","unstructured":"Gomoll\u00f3n F, Garc\u00eda-L\u00f3pez S, Sicilia B, Gisbert JP, Hinojosa J (2013) Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU. Gastroenterol Hepatol 36:1\u201347. \n                    https:\/\/doi.org\/10.1016\/j.gastrohep.2012.09.006","journal-title":"Gastroenterol Hepatol"},{"key":"3271_CR23","doi-asserted-by":"publisher","unstructured":"Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ (2018) No benefit of concomitant 5-aminosalicylates in patients with ulcerative colitis escalated to biologic therapy: pooled analysis of individual participant data from clinical trials. Am J Gastroenterol. \n                    https:\/\/doi.org\/10.1038\/s41395-018-0144-2","DOI":"10.1038\/s41395-018-0144-2"},{"key":"3271_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ajg.2009.685","volume":"105","author":"CA Jackson","year":"2010","unstructured":"Jackson CA, Clatworthy J, Robinson A, Horne R (2010) Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 105:525\u2013539. \n                    https:\/\/doi.org\/10.1038\/ajg.2009.685","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"3271_CR25","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/00365521.2018.1451915","volume":"53","author":"R Keil","year":"2018","unstructured":"Keil R, Keil R, Wasserbauer M, Z\u00e1dorov\u00e1 Z, Kojeck\u00fd V, Hlava \u0160, \u0160t'ov\u00ed\u010dek J, Chud\u00fd J, Rozn\u011btinsk\u00e1 M, Dr\u00e1bek J, Kubi\u0161ov\u00e1 N, Lochmannov\u00e1 J (2018) Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study. Scand J Gastroenterol 53(4):459\u2013465. \n                    https:\/\/doi.org\/10.1080\/00365521.2018.1451915","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"3271_CR26","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1365-2036.2010.04445.x","volume":"32","author":"SV Kane","year":"2010","unstructured":"Kane SV, Robinson A (2010) Review article: understanding adherence to medication in ulcerative colitis \u2013 innovative thinking and evolving concepts. Aliment Pharmacol Ther 32(9):1051\u20131058. \n                    https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04445.x","journal-title":"Aliment Pharmacol Ther"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-019-03271-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00384-019-03271-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-019-03271-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T23:25:32Z","timestamp":1586215532000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00384-019-03271-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["3271"],"URL":"https:\/\/doi.org\/10.1007\/s00384-019-03271-9","relation":{},"ISSN":["0179-1958","1432-1262"],"issn-type":[{"value":"0179-1958","type":"print"},{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"21 February 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M. Minguez has served as a speaker, a consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Janssen, Shire Pharmaceuticals, Allergan.M.M. Bosca-Watts declares educational activities, research projects, scientific meetings, and advisory boards sponsored by MSD, Ferring, Abbvie, Janssen, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All study participants, or their legal guardian, provided informed written consent prior to study enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}},{"value":"The study was reviewed and approved by the University Clinic Hospital of Valencia, Institutional Review Board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board approval"}}]}}